|
1
|
Imberti C, Lok J, Coverdale JPC, Carter OWL, Fry ME, Postings ML, Kim J, Firth G, Blower PJ, Sadler PJ. Radiometal-Labeled Photoactivatable Pt(IV) Anticancer Complex for Theranostic Phototherapy. Inorg Chem 2023; 62:20745-20753. [PMID: 37643591 PMCID: PMC10731635 DOI: 10.1021/acs.inorgchem.3c02245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2023] [Indexed: 08/31/2023]
Abstract
A novel photoactivatable Pt(IV) diazido anticancer agent, Pt-succ-DFO, bearing a pendant deferoxamine (DFO) siderophore for radiometal chelation, has been synthesized for the study of its in vivo behavior with radionuclide imaging. Pt-succ-DFO complexation of Fe(III) and Ga(III) ions yielded new heterobimetallic complexes that maintain the photoactivation properties and photocytotoxicity of the parent Pt complex in human cancer cell lines. Radiolabeled Pt-succ-DFO-68Ga (t1/2 = 68 min, positron emitter) was readily prepared under mild conditions and was stable in the dark upon incubation with human serum. PET imaging of Pt-succ-DFO-68Ga in healthy mice revealed a promising biodistribution profile with rapid renal excretion and limited organ accumulation, implying that little off-target uptake is expected for this class of agents. Overall, this research provides the first in vivo imaging study of the whole-body distribution of a photoactivatable Pt(IV) azido anticancer complex and illustrates the potential of radionuclide imaging as a tool for the preclinical development of novel light-activated agents.
Collapse
Affiliation(s)
- Cinzia Imberti
- Department
of Chemistry, University of Warwick, Coventry CV4 7AL, U.K.
| | - Jamie Lok
- Department
of Chemistry, University of Warwick, Coventry CV4 7AL, U.K.
| | - James P. C. Coverdale
- School
of Pharmacy, Institute of Clinical Sciences, University of Birmingham, Birmingham B15 2TT, U.K.
| | | | - Millie E. Fry
- School
of Pharmacy, Institute of Clinical Sciences, University of Birmingham, Birmingham B15 2TT, U.K.
| | - Miles L. Postings
- Department
of Chemistry, University of Warwick, Coventry CV4 7AL, U.K.
| | - Jana Kim
- School
of Biomedical Engineering & Imaging Sciences, King’s College London, St Thomas’ Hospital, London SE1 7EH, U.K.
| | - George Firth
- School
of Biomedical Engineering & Imaging Sciences, King’s College London, St Thomas’ Hospital, London SE1 7EH, U.K.
| | - Philip J. Blower
- School
of Biomedical Engineering & Imaging Sciences, King’s College London, St Thomas’ Hospital, London SE1 7EH, U.K.
| | - Peter J. Sadler
- Department
of Chemistry, University of Warwick, Coventry CV4 7AL, U.K.
| |
Collapse
|
|
2
|
Dao A, Wu H, Wei S, Huang H. Novel Ru(II) complexes with multiple anticancer photoreactivity: ligand exchange, photoredox catalysis, reactive oxygen generation and endoperoxide formation. Phys Chem Chem Phys 2023; 25:20001-20008. [PMID: 37461395 DOI: 10.1039/d3cp02346j] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/27/2023]
Abstract
The hypoxic microenvironment and drug resistance of cancer cells have become a huge threat for clinical anticancer therapy. Anticancer phototherapy providing spatial and temporal control over drug activation may conquer this problem. Herein, we report a novel photoactivated Ru(II) complex (Ru2) with multiple activities including photochemotherapy, photodynamic and photocatalytic therapy, and endoperoxide formation. Upon white light irradiation, Ru2 can dissociate the coordinating ligands and form endoperoxides, produce diverse reactive oxygen species and catalytically oxidize cellular coenzymes. As a result, Ru2 shows promising antiproliferation activity toward cisplatin and 5-fluorouracil resistant tumor cell lines under normoxia and hypoxia. The multifunctional design strategy of metal-based anticancer drugs offers novel efficient therapeutics to combat drug-resistant cancer cells under hypoxia.
Collapse
Affiliation(s)
- Anyi Dao
- School of Pharmaceutical Science (Shenzhen), Shenzhen campus of Sun Yat-sen University, No. 66, Gongchang Road, Shenzhen 518107, China.
| | - Haorui Wu
- School of Pharmaceutical Science (Shenzhen), Shenzhen campus of Sun Yat-sen University, No. 66, Gongchang Road, Shenzhen 518107, China.
| | - Siqi Wei
- School of Pharmaceutical Science (Shenzhen), Shenzhen campus of Sun Yat-sen University, No. 66, Gongchang Road, Shenzhen 518107, China.
| | - Huaiyi Huang
- School of Pharmaceutical Science (Shenzhen), Shenzhen campus of Sun Yat-sen University, No. 66, Gongchang Road, Shenzhen 518107, China.
| |
Collapse
|
|
3
|
Huang J, Ding W, Zhu X, Li B, Zeng F, Wu K, Wu X, Wang F. Ligand Evolution in the Photoactivatable Platinum(IV) Anticancer Prodrugs. Front Chem 2022; 10:876410. [PMID: 35755267 PMCID: PMC9218644 DOI: 10.3389/fchem.2022.876410] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2022] [Accepted: 04/22/2022] [Indexed: 11/24/2022] Open
Abstract
Photoactivatable Pt(IV) anticancer prodrugs with the structure of [PtIV(N1)(N2)(L1)(L2)(A1)(A2)], where N1 and N2 are non-leaving nitrogen donor ligands, L1 and L2 are leaving ligands, and A1 and A2 are axial ligands, have attracted increasing attention due to their promising photo-cytotoxicity even to cisplatin-resistant cancer cells. These photochemotherapeutic prodrugs have high dark-stability under physiological conditions, while they can be activated by visible light restrained at the disease areas, as a consequence showing higher spatial and temporal controllability and much more safety than conventional chemotherapy. The coordinated ligands to the Pt center have been proved to be pivotal in determining the function and activity of the photoactivatable Pt(IV) prodrugs. In this review, we will focus on the development of the coordinated ligands in such Pt(IV) prodrugs and discuss the effects of diverse ligands on their photochemistry and photoactivity as well as the future evolution directions of the ligands. We hope this review can help to facilitate the design and development of novel photoactivatable Pt(IV) anticancer prodrugs.
Collapse
Affiliation(s)
- Jingjing Huang
- Key Laboratory of Hubei Province for Coal Conversion and New Carbon Materials, School of Chemistry and Chemical Engineering, Wuhan University of Science and Technology, Wuhan, China
| | - Weize Ding
- Key Laboratory of Hubei Province for Coal Conversion and New Carbon Materials, School of Chemistry and Chemical Engineering, Wuhan University of Science and Technology, Wuhan, China
| | - Xingfan Zhu
- Key Laboratory of Hubei Province for Coal Conversion and New Carbon Materials, School of Chemistry and Chemical Engineering, Wuhan University of Science and Technology, Wuhan, China
| | - Bingbing Li
- Key Laboratory of Hubei Province for Coal Conversion and New Carbon Materials, School of Chemistry and Chemical Engineering, Wuhan University of Science and Technology, Wuhan, China
| | - Fangang Zeng
- School of Environment and Natural Resources, Renmin University of China, Beijing, China
| | - Kui Wu
- Key Laboratory of Hubei Province for Coal Conversion and New Carbon Materials, School of Chemistry and Chemical Engineering, Wuhan University of Science and Technology, Wuhan, China
| | - Xiaoqin Wu
- Key Laboratory of Hubei Province for Coal Conversion and New Carbon Materials, School of Chemistry and Chemical Engineering, Wuhan University of Science and Technology, Wuhan, China
| | - Fuyi Wang
- College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.,Beijing National Laboratory for Molecular Sciences, National Centre for Mass Spectrometry in Beijing, CAS Key Laboratory of Analytical Chemistry for Living Biosystems, Institute of Chemistry, Chinese Academy of Sciences, Beijing, China.,University of Chinese Academy of Sciences, Beijing, China
| |
Collapse
|
|
4
|
Research progress of azido-containing Pt(IV) antitumor compounds. Eur J Med Chem 2021; 227:113927. [PMID: 34695775 DOI: 10.1016/j.ejmech.2021.113927] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2021] [Revised: 10/10/2021] [Accepted: 10/13/2021] [Indexed: 12/11/2022]
Abstract
Cancer is a long-known incurable disease, and the medical use of cisplatin has been a significant discovery. However, the side-effects of cisplatin necessitate the development of new and improved drug. Therefore, in this study, we focused on the photoactivatable Pt(IV) compounds Pt[(X1)(X2)(Y1)(Y2)(N3)2], which have a completely novel mechanism of action. Pt(IV) can efficiently overcome the side-effects of cisplatin and other drugs. Here, we have demonstrated, summarized and discussed the effects and mechanism of these compounds. Compared to the relevant articles in the literature, we have provided a more detailed introduction and a made comprehensive classification of these compounds. We believe that our results can effectively provide a reference for the development of these drugs.
Collapse
|